Données supplé­mentaires 1 de Nivolumab adjuvant versus Ipilimumab dans le mélanome réséqué de stade III/IV : efficacité sur 5 ans et résultats sur les biomarqueurs issus de CheckMate 238

Larkin et al. (Mon,) ont étudié cette question.

www.synapsesocial.com/papers/68e586b5b6db643587522eca — DOI: https://doi.org/10.1158/1078-0432.27030961.v1

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Supplementary Data 1 from Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238· 2024
2. Data from Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238· 2024
3. Data from SALVO: Single Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma· 2024
4. Long-term survival after neoadjuvant low-dose ipilimumab plus high-dose nivolumab in resectable stage III melanoma: the 5-year survival-update and biomarker analysis from the PRADO-trial· 2025 · 1 citations
5. Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data· 2024 · 3 citations